Alector, Inc.
NASDAQ: ALEC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Arnon Rosenthal
- Employees
- 175
- Headquarters
- South San Francisco, United States
- IPO year
- 2019
- Market cap
- $198.7M
- Website
- https://www.alector.com
Loading ALEC…
Loading profile data…Frequently asked questions about ALEC
What does Alector, Inc. (ALEC) do?
Alector, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering new treatments for neurodegenerative disorders. A key program in its pipeline is AL001, a humanized recombinant monoclonal antibody currently undergoing Phase III clinical trials. This investigational therapy targets a range of severe conditions, including fronto...
Where does ALEC trade?
Alector, Inc. (ALEC) trades on the NASDAQ Global Select.
What sector is ALEC in?
Alector, Inc. (ALEC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Alector, Inc.?
Arnon Rosenthal is the chief executive officer of Alector, Inc. (ALEC).
Where is Alector, Inc. headquartered?
Alector, Inc. is headquartered in United States.
Does ALEC pay a dividend?
Alector, Inc. (ALEC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALEC go public?
Alector, Inc. (ALEC) completed its initial public offering in 2019.